Alpha Thalassemia Market Research Report - Forecast till 2030

Alpha Thalassemia Market research report: by type (hb bart syndrome, hbh disease, silent carrier state, and trait.), by diagnosis (perinatal testing, prenatal testing, and pre-implantation), Treatment, End user -forecast till 2030

ID: MRFR/LS/3712-HCR | November 2022 | Region: Global | 90 Pages         

Alpha Thalassemia Market Speak to Analyst Request a Free Sample

Alpha Thalassemia Market Scenario


The alpha thalassemia market is projected to reach USD 6,658.30 Million by 2030 at 10.5% CAGR during the forecast period 2022-2030.
Thalassemia is a blood disorder that causes abnormal production of hemoglobin in an affected person. It is a genetic disorder inherited from parents. Hemoglobin carries oxygen in the blood and is produced by two proteins called alpha globin and beta globin. A person is required to inherit a total of four genes to produce alpha globin protein, two of these genes are inherited from the parents. This blood disorder is caused due to abnormality or mutation in one or more genes responsible for hemoglobin production. When a person inherits only one affected gene from parents then the person becomes a carrier of thalassemia. Since thalassemia is an inherited disorder; one of the parents must be a carrier for thalassemia. When both the parents are carriers then the risk of giving birth to a thalassemia affected child is quite high. Thalassemia is generally of two types: alpha thalassemia and beta thalassemia.


Alpha thalassemia is a blood disorder that reduces the production of hemoglobin. Hb Bart syndrome is the most commonly occurring type which is characterized by hydrops fetalis, a condition in which excess fluid builds up in the body before birth.


Globally, thalassemia affects approximately 7% of the population out of which its alpha type affects 3% with many of them being transfusion-dependent patients. The alpha thalassemia market is likely to be driven by the growing market of bone marrow transplant and blood transfusion therapy, supported by high numbers of transfusion-dependent patients. Key trends in alpha thalassemia market include progressing drug pipeline, rising scope of gene therapy and growing awareness towards thalassemia. However, there are some factors which can hinder the growth of the market including regulatory changes, associated risks and the high cost of treatment.


Key Players


Some of key the players in the alpha thalassemia market are GlaxoSmithKline Plc, Celgene, Bellicum Pharmaceuticals, Lonza group, Acceleron Pharma, BlueBird Bio, Sangamo Biosciences.


The other prominent players include Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Calimmune Inc, CRISPR Therapeutics, Editas Medicine Inc, Errant Gene Therapeutics LLC, Gamida Cell Ltd, Gilead Sciences Inc, Incyte Corp, Ionis Pharmaceuticals Inc, IRBM Science Park SpA, Johnson & Johnson, Kiadis Pharma NV, La Jolla Pharmaceutical Company, Merck & Co Inc, PharmaEssentia Corp, Protagonist Therapeutics Inc, Sangamo Therapeutics Inc and Zydus Cadila Healthcare Ltd.


Intended Audience



  • Alpha thalassemia drug Suppliers

  • Alpha thalassemia drug Manufacturers

  • Research And Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


Segmentation


The alpha thalassemia is segmented on the basis of type, diagnosis, treatment, and end-users.


On the basis of the type, the alpha thalassemia market is segmented into hemoglobin Bart hydrops fetalis syndrome or Hb Bart syndrome (the more severe form), HbH disease, silent carrier state, and trait.


On the basis of the diagnosis, the alpha thalassemia market is segmented into perinatal testing, prenatal testing, and pre-implantation. Further, the perinatal testing sub-categorized into complete blood count (CBC) And DNA testing. The prenatal testing further sub-segment into prenatal genetic testing and chorionic villus sampling. 


On the basis of the treatment, the alpha thalassemia market is segmented into blood transfusions, iron chelation, bone marrow, or stem cell transplant, surgery and gene therapy.


On the basis of the end-user, the alpha thalassemia market is segmented into hospitals, biotechnological laboratories, diagnostic laboratories, educational research institutes, pharmaceutical industries and others.


Regional Analysis


The alpha thalassemia market consists of regions namely Americas, Europe, Asia Pacific, the Middle East and Africa


North America is projected to hold the largest share of the alpha thalassemia market due to the presence of superior research and development base, strong regional economies, and greater emphasis on disease prevention and wellness by the governments. The U.S. is expected to be the first region to start selling thalassemia drugs due to developing drug pipeline and later on, alpha thalassemia market penetration of thalassemia drugs would occur in Europe. North America and Europe have a high prevalence of severe forms of alpha-thalassemia which would result in a high demand for thalassemia drugs in future.


The tropical regions are more prone to possess high numbers of patients with alpha thalassemia like Nigeria, Sudan, Chad, Columbia etc. followed by few South Asian countries. Research Institutes and Pharmaceutical companies, growing usage for alpha thalassemia testing and technological advancements, rising awareness are few factors driving alpha thalassemia market growth in the region. Few Asian countries like Myanmar and Thailand also have a high number of alpha thalassemia patients.


The key factors which are anticipated to drive this market include rising healthcare expenditure, rising spending on stem cell therapy research and development and rising population in the East-Asia and Pacific region of the world. Some of the noteworthy developments of this industry include the advances in the iron chelation therapy, development of gene therapy and fetal hemoglobin inducers as potential curatives for thalassemia. However, the growth of the respective industry is challenged by the high cost of treatments, lack of alternative treatments and unmet market of the Asia-Pacific. The alpha thalassemia market is expected to grow in future with the mounting prevalence of thalassemia, rising Asian population, increasing healthcare expenditure, rising spending on pharmaceuticals R&D and stem cell therapy research.


The Middle East region is expected to grow at a faster rate due to the factors such as the extensive development of health care infrastructure and growing emphasis on research and development in the health care sector.


Alpha Thalassemia Market, by Region



  • Americas


    • North America


      • US

      • Canada


    • Latin America


  • Europe


    • Western Europe


      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe


    • Eastern Europe


  • Asia-Pacific


    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific


  • The Middle East & Africa


    • Middle East

    • Africa



Research Methodology
Alpha Thalassemia Market

Sources: Annual reports, Press release, White paper, and Company presentation


The report for Alpha Thalassemia Market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.



Report Scope:

Report Attribute/Metric Details
  Market Size   2030: USD 6,658.30 Million
  CAGR   10.5%(2022-2030)
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Diagnosis, Treatment, and End-users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Calimmune Inc, CRISPR Therapeutics, Editas Medicine Inc, Errant Gene Therapeutics LLC, Gamida Cell Ltd, Gilead Sciences Inc, Incyte Corp, Ionis Pharmaceuticals Inc, IRBM Science Park SpA, Johnson & Johnson, Kiadis Pharma NV, La Jolla Pharmaceutical Company, Merck & Co Inc, PharmaEssentia Corp, Protagonist Therapeutics Inc, Sangamo Therapeutics Inc and Zydus Cadila Healthcare Ltd.
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Rising healthcare expenditure
  • Rising spending on stem cell therapy research
  • Development and rising population


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The alpha thalassemia market is projected to grow at an 10.5% CAGR between 2022-2030.

    North America is projected to dominate the alpha thalassemia market.

    Different end users of the alpha thalassemia market include pharmaceutical industries, educational research institutes, diagnostic laboratories, biotechnological laboratories, hospitals, and others.

    Growing awareness about thalassemia and progressing drug pipeline are the key factors driving the alpha thalassemia market growth.

    High treatment cost, associated risks, and regulatory changes may limit the alpha thalassemia market growth.